3 reports

SAES WERE REPORTED FOR ONE IN ## PATIENTS IN THE PICLIDENOSON GROUP AND ONE IN ## PATIENTS IN THE PLACEBO GROUP (CAN-FITE BIOPHARMA, NCT##).

  • Biopharmaceutical
  • Biosimilar
  • Hospital
  • Therapy
  • Oceania
  • KEY EVENTS IMPACTING SALES FOR RA IN AUSTRALIA, 2015-2025

IN JUNE 2016, CAN-FITE BIOPHARMA ANNOUNCED THAT IT HAD REACHED AN AGREEMENT WITH THE EMA FOR CF-##' S PHASE III TRIAL DESIGN (CAN-FITE BIOPHARMA; PRESS RELEASE; JUNE ##, 2016).

  • Biopharmaceutical
  • Oceania
  • AbbVie Inc.
  • Pfizer Inc.
  • Remicade group

ARRAY BIOPHARMA' S BRAF + MEK INHIBITOR COMBINATION IS IN THE PIPELINE FOR MELANOMA.

  • Biopharmaceutical
  • Hospital
  • Targeted Therapy
  • Therapy
  • Oceania